TBH Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Procedure-driven DemandTeleflex benefits from recurring consumable demand embedded in routine and complex hospital procedures. Broad use across vascular access, anesthesia, surgery, urology and critical care can support repeat purchasing, helping make revenue less dependent on one-time capital sales.
Deleveraging And Capital AllocationThe OEM divestiture materially improves strategic focus while providing cash to reduce debt and repurchase shares. Lower pro forma net leverage and reduced interest expense can strengthen financial flexibility, support earnings, and provide greater capacity for future investment.
Innovation And Clinical PipelineFDA approval for EZPLAZ and continued Freesolve clinical progress expand Teleflex’s innovation pipeline in emergency medicine and interventional therapies. Combined with R&D at 7.9% of sales, these milestones may support future product adoption and portfolio differentiation.
Bears Say
Severe Profitability DeteriorationThe large TTM net loss and declining revenue indicate that recent earnings power has weakened substantially from prior profitable periods. Even with solid gross margin, sustained operating losses can constrain reinvestment, reduce resilience, and make balance-sheet improvement more dependent on execution.
Interventional Integration And Growth PressureThe prolonged VI integration is affecting order-to-cash processes, distributor transitions and sales-force alignment, limiting near-term Interventional performance. Lower company-wide revenue guidance signals that execution challenges could persist across the next several quarters and delay expected growth benefits.
Higher Leverage And Weaker CoverageAlthough divestiture proceeds support debt reduction, Teleflex still carries materially higher leverage than in earlier years and has weaker obligation coverage. This combination reduces financial flexibility, increases dependence on consistent cash generation, and leaves less room for operating setbacks or integration costs.
TBH FAQ
What was Teleflex Inc’s price range in the past 12 months?
Currently, no data Available
What is Teleflex Inc’s market cap?
Teleflex Inc’s market cap is CHF4.37B.
When is Teleflex Inc’s upcoming earnings report date?
Teleflex Inc’s upcoming earnings report date is Oct 22, 2026 which is in 17 days.
How were Teleflex Inc’s earnings last quarter?
Teleflex Inc released its earnings results on Aug 06, 2026. The company reported CHF1.462 earnings per share for the quarter, beating the consensus estimate of CHF1.064 by CHF0.398.
Is Teleflex Inc overvalued?
According to Wall Street analysts Teleflex Inc’s price is currently Undervalued.
Does Teleflex Inc pay dividends?
Teleflex Inc does not currently pay dividends.
What is Teleflex Inc’s EPS estimate?
Teleflex Inc’s EPS estimate is 1.58.
How many shares outstanding does Teleflex Inc have?
Teleflex Inc has 42,372,400 shares outstanding.
What happened to Teleflex Inc’s price movement after its last earnings report?
Teleflex Inc reported an EPS of CHF1.462 in its last earnings report, beating expectations of CHF1.064. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Teleflex Inc?
Currently, no hedge funds are holding shares in CH:TBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teleflex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF131.10 (― Upside)
CHF131.10 (― Upside)
Blogger Sentiment
Bullish
CH:TBH Sentiment 67%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
1.31%
Trailing 12-Months
Asset Growth
-7.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Teleflex Inc
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
TBH Company Deck
TBH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic outlook: management reported a quarter that beat on revenue, margin and EPS expectations, closed a sizable OEM divestiture generating ~$1.5B of proceeds to accelerate debt paydown and share repurchases, and highlighted meaningful innovation and R&D progress (EZPLAZ approval, Freesolve milestones). However, the company is navigating near-term headwinds — primarily slower-than-expected integration of the VI acquisition that pressured Interventional revenue, margin compression from tariffs and acquisition mix, stranded costs and regulatory timing on remaining divestitures. Management reiterated a clear plan to reduce debt, return capital, increase R&D focus and deliver margin improvement in 2027, and raised FY EPS guidance while trimming FY revenue growth guidance. On balance, the positive strategic moves, capital returns and innovation progress outweigh the transient integration and margin challenges, with improved financial profile expected in 2027.View all CH:TBH earnings summariesTBH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
―AngioDynamics
―
Baxter International
―
Becton Dickinson
―
ICU Medical
―
Merit Medical Systems
―










